Aligos Therapeutics (ALGS) Enterprise Value (2019 - 2026)

Aligos Therapeutics has reported Enterprise Value for 8 years, with the latest figure at -$79.8 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 42.16% year-over-year to -$79.8 million; the trailing twelve-month figure through Mar 2026 stood at -$79.8 million (up 42.16% YoY), and the FY2025 full-year result was -$77.8 million, down 36.71% from the prior year.
• Enterprise Value for Q1 2026 stood at -$79.8 million, down from -$77.8 million in the prior quarter.
• The five-year high for Enterprise Value was -$18.8 million in Q2 2025, with the low at -$201.3 million in Q1 2024.
• Historically, Enterprise Value has averaged -$103.8 million across 5 years, with a median of -$90.8 million in 2023.
• Annual changes were most pronounced in 2024 — Enterprise Value tumbled 154.58% — and 2025, when it soared 80.15%.
• Aligos Therapeutics' Enterprise Value stood at -$81.5 million in 2022, then plunged by 66.71% to -$135.8 million in 2023, then surged by 58.07% to -$56.9 million in 2024, then plunged by 36.71% to -$77.8 million in 2025, then retreated by 2.55% to -$79.8 million in 2026.
• The last three Enterprise Value figures came in at -$79.8 million (Q1 2026), -$77.8 million (Q4 2025), and -$156.2 million (Q3 2025), per Business Quant data.